< Back

Goodbody Health Limited

AQSE Growth Markets (Equity) -
Goodbody Health is an established health and wellness company that operates within the United Kingdom and Europe as a trusted aggregator, distributor and retailer of quality, accredited wellness products and diagnostic services to provides a unique ‘frontline’ healthcare service in the local community and enable customers to manage their health care digitally. It operates under the mantra ‘Know More. Live Better’ to provide healthcare testing services in the local community.

goodbodyhealth.com
Symbol Ccy Code Bid Ask Share Price (Mid) Previous Close Volume Last Traded
GDBY GBX 10 12 11 11 3048 30.09.22

MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.

Key Information

  
Market Cap: £4,014,590
ISIN:GG00BP6KMG85
Par:
Inst Type:Ordinaries
Symbol:GDBY
MIFID Status:MTF
Tradable securities in issue:36,496,276
Sector:Health Care Equipment & Services
% daily price change:0.00%

Latest Trades

Date & Time Volume Price
30.09.22  |  12:57:30142310.4
30.09.22  |  10:36:14162510.4
29.09.22  |  13:42:04910
29.09.22  |  12:11:1541110
29.09.22  |  09:29:26210.01
29.09.22  |  08:40:3096110.4
28.09.22  |  15:33:47310
27.09.22  |  08:21:14129710.01
26.09.22  |  16:36:062885112
26.09.22  |  16:20:011868110.01
View all trades >

Latest Announcements

Date & Time Title
30.08.22  |  15:30:00Goodbody Health Ltd - Director/PDMR Shareholding
23.08.22  |  15:30:00Goodbody Health Inc. - Update on Completion of Continuation
19.08.22  |  07:00:00Goodbody Health Inc. - Half year financial results Q2 2022
10.08.22  |  13:00:00Goodbody Health Inc. - Result of AGM and Special Meeting
14.07.22  |  07:00:00Goodbody Health Inc. - AGM and Special Meeting of Shareholders
20.06.22  |  07:00:00Goodbody Health Inc. - Genetic Risk Testing Cancer & Cardiovascular
16.06.22  |  07:00:00Goodbody Health Inc. - Care Quality Commission Registration Granted
10.06.22  |  13:00:00Goodbody Health Inc. - De-list from CSE, Re-domicile, Change of Adviser
26.05.22  |  07:00:00Goodbody Health Inc. - Launch of the Health “MOT” diagnostic test
25.05.22  |  07:00:00Goodbody Health Inc. - Goodbody publishes highest quarterly profit in Q1
View all announcements >

Financial Information

Performance

Earnings per share of -0.67p for 12/2021 has grown from -4.77p in 12/2019 or 86% over the period. Looking at this trend over the last 3 reported periods earnings are showing a growth.

Earnings per share   % growth (1)
   
 12/2020-40%
 12/2021-77%
   
Average over 3 periods+-63%
Strength in EPS trend ±
Low
High

(1) % growth is year on year % change in EPS.

Basic earnings per share are earnings from continuing and discontinued operations that are attributable to current equity holders.

Business Insight

Costs to Revenues ratio of 0.6 in 12/2021 has improved from 3 in 12/2019. Revenues over the period have increased at a faster pace than the Operating costs have increased.

Cost to Revenue ratio (2)   Multiple to Revenue
   
 12/20193.0x
 12/20203.1x
 12/20210.6x
   
Average multiple over 3 periods+1.0x
Strength of cost to revenue relationship ±
Low
High

(2) Costs include selling and admin, depreciation, amortisation and other operating costs.

Valuation

Financial Metric
Price multiple to metric
Relationship strength between metric and share price ±
  
EBITDA-331.9x
EBIT-12.1x
NI-5.7x
FCF8.1x
DPS-
Assets1.2x
CE1.8x

The Relationship Strength is statistical measure of how close the data is to a line of best-fit line between share price and the metric shown. It is scaled between zero (no relationship) and 5 (strong relationship).

In this case Capital Employed has the strongest relationship to share price, with the company's Market Capital value at 1.8x Capital Employed.

+ In cases of change in accounting period length, the average is for the last 3 periods. In all cases, it is dependent on published available data and may be for periods shorter than 3 years

± The ‘Strength’ bar shows the strength of the statistical linear relationship of the metrics shown in the chart over the last three periods of data.

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
Last results date:     31.12.21
Enterprise Value £13.14m
EV/EBITDA (331.88)
EV/EBIT (12.14)
   
PE Ratio (5.38)
PEG 272.11%
Dividend Yield -
Free Cash Yield 12.95%

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)		 31.12.21
(£'000)
Income Statement      
Revenue 1,4491,99417,058
Operating Income (EBIT) (3,553)(4,989)(1,082)
Net Income (3,798)(4,659)(2,314)
       
Balance Sheet      
Cash 1,9931,2894,904
Total Debt 621500337
Total Liabilities 1,0501,9253,775
Total Equity 3,5016,2847,068
       
Operating Margin (245.12)%(250.16)%(6.35)%
EPS - Basic (4.77)p(2.87)p(0.67)p
EPS - Growth -(39.89)%(76.69)%
Dividend Per Share ---
Average Shares Outstanding 79.60m162.45m346.18m
       
ROA (166.86%)(73.01%)(24.29%)
ROCE (179.81%)(93.08%)(15.44%)
ROE (216.93%)(95.22%)(34.66%)

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)		 31.12.21
(£'000)
Revenue 1,4491,99417,058
Cost of Revenue 6958718,127
Depreciation & Amortisation 2604711,043
Gross Profit 4956527,888
Other Operating Expenses 4,0485,6418,970
Operating Income (EBIT) (3,553)(4,989)(1,082)
Net Interest Expense 11-13
Unusual Expense (incl. Exceptionals) 23361,378
Non-Operating Expense -208227
Profit (pre-tax) (3,798)(4,787)(2,247)
Taxation -128(68)
Other Expenses and Minortity Interest ---
Net Income (3,798)(4,659)(2,314)

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)		 31.12.21
(£'000)
Cash from Operations (2,613)(2,348)1,856
Cash from Investing (493)2,412(122)
Cash from Financing 1,356(184)2,462
Other Miscellaneous ---
Net Cash Flow (1,750)(120)4,196

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >
31.12.19
(£'000)		 31.12.20
(£'000)		 31.12.21
(£'000)
Current Assets 2,7002,8887,296
Non-Current Assets 1,8515,3213,547
Total Assets 4,5528,21010,843
Current Liabilities 6001,4423,590
Non-Current Liabilities 451483185
Total Liabilities 1,0501,9253,775
Net Assets 3,5016,2847,068
Total Equity 3,5016,2847,068

Click here to download a glossary of terms.

All data provided by Fregnan.

Further Fregnan Data >

Address

Business Address

Goodbody Health Inc., The Blue Building, Stubbs Lane, Beckington Frome, Somerset, BA11 6TE, United Kingdom.

Email: enquires@goodbodyhealth.com

Phone: +44 (0) 20 7971 1255

Registered Address

PO Box 282, Oak House, Hirzel Street, St Peter Port, GY1 2NP, Guernsey.

Contacts

Corporate Adviser

Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, United Kingdom.

Email: info@pcorpfin.com

Phone: +44 (0)20 7469 0930

Registrar

Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol, BS13 8AE, United Kingdom.

Email: web.queries@computershare.co.uk

Phone: 0370 703 6191

Research


Know More - Live Better